Anavex Life Sciences Corporation
AVXL
Get informed when a big investor buys or sells
+ FollowMarket Cap$254.85M
Close$
$1.20
61.8% downside
Current Fair Value
61.8% downsideOvervalued by 61.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $254.85 Million |
|---|---|
| Enterprise Value | $128.23 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.54 |
| Beta | 1.14 |
| Outstanding Shares | 92,675,753 |
Return
| Return on Equity | -17.13% |
|---|---|
| Return on Assets | -16.19% |
| Return on Invested Capital | -29.97% |
Valuation & Multiples
| P/E Ratio | -7.03 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | 3.15 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.52 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$-0.07
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 10, 2026
EPS Estimate
$-0.08
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 20.87% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.01%▼ 42.91% |
|---|---|
| Total Invested | $4.65M▼ 96.21% |
| Investors Holding | 39▼ 160.00% |
ESG Score
No data
About Anavex Life Sciences Corporation
CEO: Christopher Missling Anavex Life Sciences Corp. is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, ...